Utilisation of antithrombotic therapy for stroke prevention in atrial fibrillation in a Sydney hospital: Then and now

International Journal of Clinical Pharmacy

Volumn 34, Issue 1, 2012, Pages 88-97

  Bajorek, Beata V ^a   Ren, Shu ^b  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Aged care; Antithrombotic agents; Aspirin; Atrial fibrillation; Australia; Clinical indicator; Drug utilisation; Elderly; Stroke; Stroke prevention; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; DIPYRIDAMOLE; WARFARIN; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT;

AGE DISTRIBUTION; AGED; ARTICLE; AUSTRALIA; CLINICAL INDICATOR; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG UTILIZATION; FEMALE; HEART ATRIUM FIBRILLATION; HEART RHYTHM; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SINUS RHYTHM; STROKE; THROMBOSIS PREVENTION; TRANSIENT ISCHEMIC ATTACK; AGE; CLINICAL PRACTICE; DRUG COMBINATION; STATISTICS; TEACHING HOSPITAL;

AGE FACTORS; AGED; AGED, 80 AND OVER; ASPIRIN; ATRIAL FIBRILLATION; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HOSPITALS, TEACHING; HUMANS; MALE; NEW SOUTH WALES; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; STROKE; WARFARIN;

EID: 84860793341     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-011-9594-y     Document Type: Article

References (22)

1. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. [erratum appears in Arch Intern Med 1994 Oct 10;154(19):2254]. Arch Intern Med. 1994;154:1449-57.
2. Bajorek BV. Stroke prevention in elderly patients with atrial fibrillation. University of Sydney, 2006, Australia: Faculty of Pharmacy; (2002).
3. Bajorek BV, Krass I, Ogle SJ, Duguid MJ, Shenfield GM. The impact of age on antithrombotic use in elderly patients with non-valvular atrial fibrillation. Australas J Ageing. 2002;21:36-41.
4. Bajorek BV, Krass I, Ogle SJ, Duguid MJ, Shenfield GM. Optimizing the use of antithrombotic therapy for atrial fibrillation in older people: a pharmacist-led multidisciplinary intervention. J Am Geriatr Soc. 2005;53:1912-20.
5. Bradley BC, Perdue KS, Tisdel KA, Gilligan DM. Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a Veterans Affairs medical center. Am J Cardiol. 2000;85:568-72.
6. Cohen N, Almoznino-Sarafian D, Alon I, Gorelik O, Koopfer M, Chachashvily S, et al. Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. Stroke. 2000;31:1217-22.
7. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol. 1991;18:349-55.
8. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255-62.
9. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans affairs stroke prevention in nonrheumatic atrial fibrillation investigators. N Engl J Med. 1992;327:1406-12.
10. Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med. 1994;154:1945-53.
11. Jackson SL, Peterson GM, Vial JH. A community-based educational intervention to improve antithrombotic drug use in atrial fibrillation. Ann Pharmacother. 2004;38:1794-9.
12. Johnston JA, Cluxton RJ, Heaton PC, Guo JJ, Moomaw CJ, Eckman MH. Predictors of warfarin use among Ohio Medicaid patients with new-onset nonvalvular atrial fibrillation. Arch Intern Med. 2003;163:1705-10.
13. Lok NS, Lau CP. Presentation and management of patients admitted with atrial fibrillation: a review of 291 cases in a regional hospital. Int J Cardiol. 1995;48:271-8.
14. Mahmud A, Bennett K, Okechukwu I, Feely J. National underuse of anti-thrombotic therapy in chronic atrial fibrillation identified from digoxin prescribing. Br J Clin Pharmacol. 2007;64:706-9.
15. McNulty SJ, Hutchinson D, Hardy KJ. Implementation of anti-thrombotic management in atrial fibrillation. Postgrad Med J. 2000;76:783-6.
16. Mead GE, Wardlaw JM, Lewis SC, McDowall M, Dennis MS. The influence of randomized trials on the use of anticoagulants for atrial fibrillation. [see comment]. Age Ageing. 1999;28: 441-6.
17. National Centre for Classification in Health (Sydney N.S.W.). The International statistical classification of diseases and related health problems, tenth revision, Australian modification (ICD-10-AM). 5th edn. National Centre for Classification in Health: Lidcombe, NSW, 2006. ISBN: 186451271.
18. New South Wales Therapeutic Advisory Group. Indicators for quality use of medicines in Australian hospitals. NSW TAG Inc., Australia, 2007, ISBN: 9780958606950.
19. Partington SL, Abid S, Teo K, Oczkowski W, O'Donnell MJ. Pre-admission warfarin use in patients with acute ischemic stroke and atrial fibrillation: the appropriate use and barriers to oral anticoagulant therapy. Thromb Res. 2007;120:663-9.
20. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989; 1:175-9.
21. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study. Final results. Circulation. 1991;84:527-39.
22. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505-11.